RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Gorjan Hrustanovic(University of California, San Francisco), Trever G. Bivona(University of California, San Francisco), Aria Vaishnavi(University of Colorado Anschutz Medical Campus), Asmin Tulpule(Memorial Sloan Kettering Cancer Center), Collin M. Blakely(City College of San Francisco), Philip C. Mack(UC Davis Comprehensive Cancer Center), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus), Amit J. Sabnis(University of California, San Francisco), Robert C. Doebele(Aurora University), Eric A. Collisson(City College of San Francisco), Rafael Rosell(Hospital Universitario Dexeus), Eiki Ichihara(Okayama University), Dana S. Neel(University of California, San Francisco), Dara L. Aisner(University of Colorado System), Victor Olivas(University of California, San Francisco), Christine M. Lovly(Dana-Farber Cancer Institute), Jennifer C. Flanagan(University of California, San Francisco), Jonathan W. Riess(University of California Davis Medical Center), Niki Karachaliou(Institut Català d'Oncologia), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Luping Lin(University of California, San Francisco), Evangelos Pazarentzos(University of California, San Francisco), Saurabh Asthana(University of California, San Francisco), Elton Chan(University of California, San Francisco), Ross A. Okimoto(City College of San Francisco)
Cited by 277
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
|Cancer Cell|2017|2.1k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k